Core Viewpoint - Jupiter Neurosciences, Inc. has announced the addition of Chris Webber as the second brand ambassador for its new longevity supplement line, Nugevia™, which is based on clinical science and innovative performance-driven technology [1][3]. Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging through a dual-path strategy that includes advancing therapeutics for CNS disorders and entering the consumer longevity market with Nugevia™ [7]. - The company’s proprietary JOTROL™ platform enhances the bioavailability of resveratrol, which is the foundation for both its therapeutic pipeline and the Nugevia™ product line [10]. Product Details - Nugevia™ features three initial formulations—GLO, MND, and PWR—designed to support cellular resilience through synergistic ingredients optimized for absorption via the JOTROL™ system [4]. - The Nugevia™ brand aims to tap into the rapidly growing longevity market, projected to reach $8 trillion by 2030, creating a revenue stream to support ongoing clinical development and enhance long-term shareholder value [5][6]. Scientific Validation - JOTROL™ has demonstrated over nine times higher bioavailability compared to traditional resveratrol products, as evidenced by a Phase I study published in reputable journals [9]. - The technology aims to provide pharmaceutical-grade bioavailability in the wellness space, targeting cognitive health, skin vitality, and cellular energy [10].

PART I – FINANCIAL INFORMATION [Item 1. Financial Statements (unaudited)](index=6&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) This section presents the unaudited condensed consolidated financial statements, including the balance sheets, statements of operations, changes in stockholders' deficit, and cash flows, along with detailed notes providing context on the company's business, accounting policies, related party transactions, debt, equity, commitments, and subsequent events [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheets (Unaudited) | Metric | June 30, 2025 | December 31, 2024 | | :-------------------------- | :-------------- | :------------------ | | Total Assets | $3,968,103 | $6,202,409 | | Cash | $1,878,247 | $3,769,510 | | Total Liabilities | $2,627,985 | $2,030,401 | | Total Stockholders' Equity | $1,340,118 | $4,172,008 | | Accumulated Deficit | $(29,803,961) | $(26,022,129) | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Net (Loss) Income and EPS (Three Months Ended June 30) | Metric | 2025 | 2024 | | :----------------------- | :----------- | :----------- | | Net (loss) income | $(2,252,965) | $313,123 | | Basic EPS | $(0.07) | $0.01 | | Diluted EPS | $(0.07) | $0.01 | Net (Loss) Income and EPS (Six Months Ended June 30) | Metric | 2025 | 2024 | | :----------------------- | :----------- | :----------- | | Net (loss) income | $(3,781,832) | $(320,977) | | Basic EPS | $(0.11) | $(0.01) | | Diluted EPS | $(0.11) | $(0.01) | - Research and Development Expenses (Six Months Ended June 30): Increased by **$1,026,449 (514%)** from **$199,744** in 2024 to **$1,226,193** in 2025[19](index=19&type=chunk)[126](index=126&type=chunk) - General and Administrative Expenses (Six Months Ended June 30): Increased by **$1,648,662 (178%)** from **$928,028** in 2024 to **$2,576,690** in 2025[19](index=19&type=chunk)[127](index=127&type=chunk) [Condensed Consolidated Statement of Changes in Stockholders' Deficit](index=8&type=section&id=Condensed%20Consolidated%20Statement%20of%20Changes%20in%20Stockholders'%20Deficit) Changes in Stockholders' Equity (Six Months Ended June 30, 2025) | Metric | Amount | | :-------------------------- | :----------- | | Total Stockholders' Equity (Dec 31, 2024) | $4,172,008 | | Stock-based compensation | $883,942 | | Shares issued for services rendered | $66,000 | | Net loss | $(3,781,832) | | Total Stockholders' Equity (June 30, 2025) | $1,340,118 | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash Flow Summary (Six Months Ended June 30) | Metric | 2025 | 2024 | | :-------------------------------- | :----------- | :----------- | | Net cash flows from operating activities | $(1,891,263) | $(172,627) | | Net cash flows from investing activities | $0 | $0 | | Net cash flows from financing activities | $0 | $159,000 | | Net Change in Cash | $(1,891,263) | $(13,627) | | Cash at End of Period | $1,878,247 | $14,851 | [Notes to the Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) [Note 1 – Organization and Description of Business](index=10&type=section&id=Note%201%20%E2%80%93%20Organization%20and%20Description%20of%20Business) - Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company focused on neuro-inflammation, particularly Parkinson's Disease, using its patented JOTROL resveratrol platform[24](index=24&type=chunk) - The company completed its IPO in December 2024, selling 2,750,000 shares at $4.00 per share for net proceeds of approximately **$9,725,213**[27](index=27&type=chunk) - The company regained compliance with Nasdaq's minimum bid price requirement on July 9, 2025, after previously receiving a non-compliance notification on March 21, 2025[28](index=28&type=chunk)[29](index=29&type=chunk)[30](index=30&type=chunk) [Note 2 – Significant Accounting Policies](index=11&type=section&id=Note%202%20%E2%80%93%20Significant%20Accounting%20Policies) - Management has substantial doubt about the company's ability to continue as a going concern due to a cumulative net loss of **$29,803,961** and negative operating cash flows of **$1,891,263** for the six months ended June 30, 2025[32](index=32&type=chunk)[33](index=33&type=chunk) - The company views its operations in two segments: (i) premium nutritional supplements and (ii) pharmaceutical operations, though financial performance is currently evaluated on a consolidated basis[34](index=34&type=chunk) - Research and development costs are expensed as incurred, with recognition based on the progress to completion of specific tasks for activities like clinical trials[39](index=39&type=chunk) [Note 3 – Related Party Transactions](index=15&type=section&id=Note%203%20%E2%80%93%20Related%20Party%20Transactions) - A note payable to the CEO for working capital totaled **$146,432** as of June 30, 2025, and December 31, 2024, accruing interest at 3% per annum[56](index=56&type=chunk) - In March 2024, a former executive relinquished **$100,000** of accrued compensation in exchange for stock options and RSUs with a grant date fair value of **$60,000**, resulting in a **$40,000** gain[59](index=59&type=chunk) [Note 4 – Accounts Payable and Accrued Expenses](index=16&type=section&id=Note%204%20%E2%80%93%20Accounts%20Payable%20and%20Accrued%20Expenses) Accounts Payable and Accrued Expenses | Category | June 30, 2025 | December 31, 2024 | | :-------------------------------- | :-------------- | :---------------- | | Accounts payable | $465,093 | $278,676 | | Professional fees | $70,890 | $40,271 | | License fee | $37,500 | $75,000 | | Credit cards | $481 | $2,536 | | **Total** | **$573,964** | **$396,483** | - Accrued compensation increased from **$1,415,093** (Dec 31, 2024) to **$1,857,919** (June 30, 2025), with payments contingent on available cash[60](index=60&type=chunk) [Note 5 – Convertible Debt and Derivative Liability](index=17&type=section&id=Note%205%20%E2%80%93%20Convertible%20Debt%20and%20Derivative%20Liability) - All convertible notes (Notes I, II, and III) were fully repaid or converted in December 2024, eliminating related interest expenses and derivative liabilities by June 30, 2025[63](index=63&type=chunk)[64](index=64&type=chunk)[65](index=65&type=chunk)[71](index=71&type=chunk) - A modification to Convertible Note II in April 2024 resulted in a gain on modification of **$951,868** and an increase to derivative liability of **$407,494**[64](index=64&type=chunk)[70](index=70&type=chunk) - The company recorded a loss of **$63,142** relating to the change in fair value of derivative liability for the six months ended June 30, 2024, with no such loss in 2025[71](index=71&type=chunk) [Note 6 – Stockholders' Equity](index=19&type=section&id=Note%206%20%E2%80%93%20Stockholders'%20Equity) - As of June 30, 2025, there were **34,833,083** shares of common stock issued and outstanding[74](index=74&type=chunk) - During the six months ended June 30, 2025, the company issued **103,186 shares** of common stock with an aggregate fair value of **$66,000** for services rendered[75](index=75&type=chunk) - The company granted **250,000 stock options** to a consultant in June 2025 with an exercise price of $0.97 per share and a grant date fair value of **$191,168**[82](index=82&type=chunk) - All **1,626,037** issued and outstanding restricted stock units vested in June 2025, making the shares freely tradeable[89](index=89&type=chunk) [Note 7 – Commitments and Contingencies](index=22&type=section&id=Note%207%20%E2%80%93%20Commitments%20and%20Contingencies) Operating Lease Summary (June 30, 2025) | Metric | Amount | | :-------------------------------- | :----------- | | Operating lease right-of-use asset, net | $46,649 | | Total lease liabilities | $46,428 | - The company entered into a Strategic Services Agreement with Dominant Treasure Health Company Limited, involving a **$2,300,000** prepaid contract expensed over three years, to accelerate product development and distribution in the Southeast Asian market[97](index=97&type=chunk) - Licensing agreements with Aquanova AG and Murdoch Children's Research Institute outline development, manufacturing, and commercialization rights for JOTROL, with associated annual license fees, approval fees, and sales royalties[100](index=100&type=chunk)[101](index=101&type=chunk)[102](index=102&type=chunk) [Note 8 – Segment Report](index=25&type=section&id=Note%208%20%E2%80%93%20Segment%20Report) - The company is transitioning its operations into two reportable segments: (i) premium nutritional supplements and (ii) pharmaceutical operations[104](index=104&type=chunk) - As of June 30, 2025, the Chief Operating Decision Maker (CODM) continues to evaluate financial performance on a consolidated basis, and discrete segment-level financial information is not yet regularly reviewed[104](index=104&type=chunk)[105](index=105&type=chunk) [Note 9 – Subsequent Events](index=26&type=section&id=Note%209%20%E2%80%93%20Subsequent%20Events) - On July 2, 2025, the Compensation Committee approved the grant of **357,448 stock options** to executives and cash bonuses totaling **$449,000**, contingent on maintaining **$3,500,000** cash on hand[107](index=107&type=chunk) - Warrants for **1,249,999 shares** were cashless exercised on July 16, 2025, resulting in **913,299 shares** issued, with an agreement to issue an additional **86,700 shares** by August 31, 2025[108](index=108&type=chunk) - Warrants for **109,376 shares** were cashless exercised on August 12, 2025, resulting in **30,547 shares** issued, with an agreement for an additional **56,954 shares** by August 31, 2025[109](index=109&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=27&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on the company's financial performance and condition, highlighting its clinical-stage pharmaceutical focus on CNS disorders and rare diseases with JOTROL, alongside its Nugevia supplement line. It reiterates the going concern doubt due to significant losses and negative cash flows, details the substantial increases in R&D and G&A expenses, and outlines financing plans [Business Overview](index=27&type=section&id=Business%20Overview) - Jupiter Neurosciences is a clinical stage research and development pharmaceutical company focused on CNS disorders and rare diseases with JOTROL, and expanding into the consumer longevity market with its Nugevia product line[114](index=114&type=chunk) - The company plans a Phase IIa clinical trial for Parkinson's Disease in Q4 2025, with results anticipated 12 months later, following promising preclinical studies[115](index=115&type=chunk) - JOTROL's Phase 1 study demonstrated resveratrol levels exceeding **800 ng/ml** (above the therapeutic threshold of **200 ng/ml**) without severe adverse events, addressing bioavailability challenges[115](index=115&type=chunk) - The company is actively pursuing market expansion in Southeast Asia through service agreements with Hong Kong firms to leverage local expertise and facilitate market entry and potential out-licensing deals[117](index=117&type=chunk)[143](index=143&type=chunk) [Financial Position](index=28&type=section&id=Financial%20Position) - The company has generated no revenues from product sales since inception[120](index=120&type=chunk) - Incurred a net loss of **$3,781,832** and negative cash flows from operations totaling **$1,891,263** for the six months ended June 30, 2025[120](index=120&type=chunk) - Accumulated a cumulative net loss since inception totaling **$29,803,961**[120](index=120&type=chunk) - Management concludes these conditions raise substantial doubt about the company's ability to continue as a going concern for at least twelve months[121](index=121&type=chunk) [Results of Operations (Three Months Ended June 30, 2025 Compared to the Three Months Ended June 30, 2024)](index=28&type=section&id=Results%20of%20Operations%20(Three%20Months%20Ended%20June%2030,%202025%20Compared%20to%20the%20Three%20Months%20Ended%20June%2030,%202024)) - Research and development expenses increased by **$658,371 (651%)** to **$759,448**, driven by Southeast Asian market development and Parkinson's disease clinical trial supplies[122](index=122&type=chunk) - General and administrative expenses increased by **$1,049,432 (230%)** to **$1,505,432**, due to full employee salaries, bonus accruals, increased legal/professional fees post-Nasdaq listing, and higher insurance/consulting costs[123](index=123&type=chunk) - Interest expense decreased by **$55,155 (98%)** to **$1,135**, as prior interest-bearing obligations were repaid or converted[124](index=124&type=chunk) [Results of Operations (Six Months Ended June 30, 2025 Compared to the Six Months Ended June 30, 2024)](index=29&type=section&id=Results%20of%20Operations%20(Six%20Months%20Ended%20June%2030,%202025%20Compared%20to%20the%20Six%20Months%20Ended%20June%2030,%202024)) - Research and development expenses increased by **$1,026,449 (514%)** to **$1,226,193**, primarily due to costs for product development and distribution in Southeast Asia and procurement of clinical trial supplies for the Parkinson's disease program[126](index=126&type=chunk) - General and administrative expenses increased by **$1,648,662 (178%)** to **$2,576,690**, attributed to full employee salaries, bonus accruals, increased legal and professional fees post-public listing, and higher insurance and consulting fees[127](index=127&type=chunk) - Interest expense decreased by **$119,682 (98%)** to **$2,364**, as all prior interest-bearing obligations were repaid or converted in prior periods[128](index=128&type=chunk) [Liquidity and Capital Resources; Plan of Operations](index=30&type=section&id=Liquidity%20and%20Capital%20Resources;%20Plan%20of%20Operations) - The company has historically financed operations through common stock sales, convertible debt, and IPO proceeds[132](index=132&type=chunk) - Management has substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative operating cash flows, and a cumulative deficit of **$29,803,961**[133](index=133&type=chunk) - Future operations depend on raising additional funds through equity, debt, licensing, or strategic collaborations, with no assurance of success on commercially reasonable terms[134](index=134&type=chunk) [Cash Flows for the Six Months Ended June 30, 2025 and 2024](index=31&type=section&id=Cash%20Flows%20for%20the%20Six%20Months%20Ended%20June%2030,%202025%20and%202024) Cash Flow Summary (Six Months Ended June 30) | Metric | 2025 | 2024 | | :-------------------------------- | :----------- | :----------- | | Net cash flows from operating activities | $(1,891,263) | $(172,627) | | Net cash flows from financing activities | $0 | $159,000 | - The increase in net cash used in operating activities was primarily due to a significant increase in net loss (**$3,781,832** in 2025 vs **$320,977** in 2024) and higher non-cash adjustments like stock-based compensation and amortization of prepaid contracts[139](index=139&type=chunk) - The decrease in net cash provided by financing activities was due to the absence of financing transactions in 2025, compared to **$109,000** from related-party notes and **$50,000** from common stock sales in 2024[140](index=140&type=chunk) [Off-balance sheet financing arrangements](index=31&type=section&id=Off-balance%20sheet%20financing%20arrangements) - The company has no off-balance sheet arrangements, obligations, assets, or liabilities that would materially affect its financial condition, results of operations, or liquidity[141](index=141&type=chunk)[142](index=142&type=chunk) [Business Development Activities](index=31&type=section&id=Business%20Development%20Activities) - The company is actively pursuing business development in the Asian region to accelerate JOTROL's drug development and commercialization, driven by strategic interest and recent patent approvals[143](index=143&type=chunk) - Service agreements with Asian firms involve equity investments and issuance of common stock for three years of services, aiming for cost-effective market penetration and potential out-licensing deals in Southeast Asia[143](index=143&type=chunk)[144](index=144&type=chunk) [Contractual Obligations](index=32&type=section&id=Contractual%20Obligations) - The company has a **$146,432** note payable to its CEO, due on demand with 3% annual interest, as of June 30, 2025[145](index=145&type=chunk) - An amount of **$85,466** was due to a company wholly owned by the CFO as of June 30, 2025, included in accrued compensation[146](index=146&type=chunk) [Critical Accounting Policies](index=32&type=section&id=Critical%20Accounting%20Policies) - The company's critical accounting policies are more fully described in Note 2 to its consolidated financial statements and its 2024 Annual Report on Form 10-K[147](index=147&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=33&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This item is marked as "Not applicable," indicating that the company does not have material market risk disclosures to report for the period - The company has no material quantitative and qualitative disclosures about market risk to report[148](index=148&type=chunk) [Item 4. Controls and Procedures](index=33&type=section&id=Item%204.%20Controls%20and%20Procedures) As of June 30, 2025, management, with the participation of the CEO and CFO, concluded that the company's disclosure controls and procedures were effective. No material changes in internal control over financial reporting occurred during the quarter [Evaluation of Disclosure Controls and Procedures](index=33&type=section&id=Evaluation%20of%20Disclosure%20Controls%20and%20Procedures) - As of June 30, 2025, the company's disclosure controls and procedures were evaluated by management, including the CEO and CFO, and concluded to be effective[149](index=149&type=chunk) - Disclosure controls and procedures provide only reasonable, not absolute, assurance that objectives are met, acknowledging inherent limitations and resource constraints[150](index=150&type=chunk) [Changes in Internal Control over Financial Reporting](index=33&type=section&id=Changes%20in%20Internal%20Control%20over%20Financial%20Reporting) - There were no changes in internal control over financial reporting during the most recent fiscal quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[151](index=151&type=chunk) PART II – OTHER INFORMATION [Item 1. Legal Proceedings](index=34&type=section&id=Item%201.%20Legal%20Proceedings) The company may become involved in legal proceedings in the ordinary course of business, but it does not anticipate that their resolution would have a material adverse effect on its business, financial condition, or results of operations - Legal proceedings arising in the ordinary course of business are not anticipated to have a material adverse effect on the company's financial condition or results of operations[153](index=153&type=chunk) [Item 1A. Risk Factors](index=34&type=section&id=Item%201A.%20Risk%20Factors) Investors are advised to carefully consider the risk factors detailed in the company's Annual Report on Form 10-K for fiscal year ended December 31, 2024, as these, along with other unknown factors, could materially impact the business - Investors should carefully consider the risk factors discussed in the Annual Report on Form 10-K for fiscal year ended December 31, 2024[154](index=154&type=chunk) - Other unknown or unpredictable factors could also materially adversely affect the business, financial condition, or future results[154](index=154&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=34&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company issued 103,816 shares of common stock for services rendered to a marketing firm and an investor relations firm on April 23, 2025, with an aggregate fair value of $66,000. Additionally, 250,000 options were granted to a consultant on June 10, 2025. All these transactions were exempt from registration under Section 4(a)(2) of the Securities Act - On April 23, 2025, the company issued **103,816 shares** of common stock (25,000 to a marketing firm and 78,816 to an investor relations firm) with an aggregate grant date fair value of **$66,000** for services rendered[155](index=155&type=chunk) - On June 10, 2025, the company granted **250,000 options** to a consultant with an exercise price of $0.67 per share, vesting 25% immediately and the remainder monthly[156](index=156&type=chunk) - These transactions were exempt from registration in reliance on Section 4(a)(2) of the Securities Act of 1933[157](index=157&type=chunk) [Item 3. Defaults Upon Senior Securities](index=34&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities for the period - No defaults upon senior securities were reported[158](index=158&type=chunk) [Item 4. Mine Safety Disclosures](index=34&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is marked as "Not applicable," indicating no mine safety disclosures are relevant to the company - The company has no mine safety disclosures to report[159](index=159&type=chunk) [Item 5. Other Information](index=34&type=section&id=Item%205.%20Other%20Information) During the three months ended June 30, 2025, no director or officer of the company adopted, modified, or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" - No director or officer adopted, modified, or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2025[160](index=160&type=chunk) [Item 6. Exhibits](index=34&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including certifications from the Principal Executive Officer and Principal Financial Officer, and various Inline XBRL documents - Exhibits include certifications of Principal Executive Officer and Principal Financial Officer (31.1, 31.2, 32.1, 32.2) and Inline XBRL documents (101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB, 101.PRE, 104)[161](index=161&type=chunk)[162](index=162&type=chunk)[163](index=163&type=chunk) [Signatures](index=36&type=section&id=Signatures) The report is duly signed on behalf of Jupiter Neurosciences, Inc. by Christer Rosén, Chief Executive Officer, and Saleem Elmasri, Chief Financial Officer, on August 18, 2025 - The report was signed by Christer Rosén, Chief Executive Officer, and Saleem Elmasri, Chief Financial Officer, on August 18, 2025[166](index=166&type=chunk)

Core Insights - Jupiter Neurosciences, Inc. has launched Nugevia MND, a supplement aimed at enhancing cognitive function and supporting brain health, tapping into the $8 trillion longevity and wellness markets [1][4] - Nugevia MND combines JOTROL, a proprietary resveratrol-based platform, with NovaSOL Curcumin to target neuroprotective pathways and improve cognitive resilience [2][4] - The product is positioned to generate high-margin revenue by appealing to aging populations concerned about cognitive decline, while also complementing Jupiter's pharmaceutical pipeline [4][8] Product Details - Nugevia MND is designed to improve memory, clarity, executive function, and support mitochondrial function in brain cells, while reducing neuroinflammation and oxidative stress [7][8] - The supplement will be available through direct-to-consumer e-commerce platforms starting Fall 2025, with a recommended daily regimen of two capsules [4] Strategic Importance - The launch of Nugevia MND represents a strategic move for Jupiter to leverage its expertise in central nervous system (CNS) therapeutics within the consumer health market [3][4] - Insights gained from consumer use of MND and biomarker data from ongoing clinical trials will inform future cognitive health programs [3][4] Scientific Foundation - JOTROL has demonstrated over nine times higher bioavailability compared to traditional resveratrol products, addressing previous issues of poor absorption and gastrointestinal side effects [9][10] - The product line aims to bring clinical-grade science into the wellness space, supporting mental clarity and cellular energy [11]

Core Insights - Jupiter Neurosciences, Inc. is advancing its proprietary resveratrol-based platform, JOTROL, which offers significant advantages over traditional resveratrol formulations [1][3][10] - JOTROL has demonstrated a nine-fold increase in bioavailability compared to conventional resveratrol, while avoiding gastrointestinal side effects [3][7][10] - The company is progressing JOTROL towards a Phase IIa trial for Parkinson's Disease, supported by promising preclinical data [4][8][10] Scientific and Clinical Advantages - Resveratrol is known for its antioxidant, mitochondrial, and anti-inflammatory properties, but its therapeutic use has been limited due to poor bioavailability and GI side effects [2][9] - JOTROL promotes mitochondrial biogenesis and reduces neuroinflammation, addressing key factors in neurodegenerative diseases and aging [5][6] Product Development and Market Strategy - JOTROL is not only aimed at pharmaceutical applications but also serves as the foundation for the Nugevia consumer product line, targeting cognitive health, mitochondrial energy, and skin vitality [4][11] - The Nugevia product line is set to launch in Q3 2025, leveraging the same delivery technology as JOTROL to provide clinical-grade bioavailability in the wellness market [11] Intellectual Property and Market Potential - The company has secured intellectual property rights for JOTROL in major markets including the U.S., EU, China, Japan, and Hong Kong, valid through 2036 [7] - JOTROL's ability to cross the blood-brain barrier positions it as a potential treatment for CNS disorders such as Parkinson's and Alzheimer's [7][8]

Core Points - Jupiter Neurosciences, Inc. has regained compliance with Nasdaq's minimum share price requirement, confirming an average closing share price of at least $1.00 for 13 consecutive days [1][2] - The company is focused on developing JOTROL, a patented resveratrol-based platform, targeting neuroinflammation and promoting healthy aging [3] Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company with a dual-path strategy addressing central nervous system (CNS) disorders and rare diseases, while also entering the consumer longevity market with its Nugevia product line [3] - The therapeutic pipeline includes a Phase IIa trial for Parkinson's disease and targets conditions such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS [3]

Core Insights - Jupiter Neurosciences, Inc. has launched Nugevia PWR, a mitochondrial health supplement aimed at supporting cellular energy, endurance, and recovery, targeting a growing market projected to reach $8 trillion by 2030 [1][4][6] Product Overview - Nugevia PWR is formulated with JOTROL and a blend of mitochondrial support ingredients to optimize energy production, protect against oxidative stress, and enhance physical performance [2][6] - The supplement is designed for adults seeking sustained strength and metabolic resilience, with a recommended dosage of two capsules per day for optimal compliance [5][6] Scientific Basis - JOTROL has shown a nine-fold increase in resveratrol bioavailability in Phase I trials, promoting mitochondrial biogenesis and energy metabolism [3][9] - The formulation includes NovaSOL solubilized CoQ10, enhancing mitochondrial energy production and muscle function, creating a synergy that improves energy, endurance, and muscle recovery [3][6] Strategic Positioning - PWR aligns with Jupiter's strategy to monetize its proprietary science across pharmaceutical and consumer markets, serving as a high-margin revenue driver [4][5] - The Nugevia product line represents both scientific achievement and a strategic revenue opportunity, differentiating itself in the crowded energy supplement space [5][6] Company Background - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on neuroinflammation and healthy aging, with a therapeutic pipeline targeting CNS disorders and a consumer longevity market expansion [6][10]

Core Insights - Jupiter Neurosciences, Inc. is launching Nugevia™ GLO, a supplement targeting the "beauty-from-within" market, focusing on skin health through clinically validated cellular science [1][2] - The product utilizes JOTROL™, a proprietary resveratrol delivery technology, and NovaSOL® Astaxanthin, enhancing skin vitality at the cellular level [2][3] - GLO is positioned as a premium supplement, appealing to a demographic of women over 35 seeking scientifically grounded skin and aging solutions [4] Product Details - Nugevia GLO is designed to support skin health by promoting cellular defense, collagen integrity, and hydration [1][4] - The supplement regimen consists of two capsules per day for optimal absorption and compliance [5] - Key benefits include enhanced collagen synthesis, improved hydration, reduced pigmentation, and protection against oxidative stress [7] Market Strategy - The launch of GLO represents a strategic shift for Jupiter into the consumer wellness sector, aiming to create a high-margin revenue stream [4] - The company anticipates significant top-line growth from the Nugevia product line, which will support clinical development and enhance long-term shareholder value [5] - Jupiter is targeting the $8 trillion longevity market, leveraging its proprietary science to reach a broader audience [2] Scientific Validation - JOTROL™ has shown a nine-fold increase in resveratrol bioavailability in Phase I trials, addressing previous issues with resveratrol's effectiveness [3][9] - The combination of JOTROL™ and Astaxanthin is expected to create a leading solution for skin health and systemic rejuvenation [3][10] - Jupiter's therapeutic pipeline includes ongoing clinical programs for CNS disorders, with JOTROL™ serving as a foundation for both therapeutic and consumer products [6][10]

Core Viewpoint - Jupiter Neurosciences, Inc. has launched a new consumer longevity supplement line called Nugevia, with Annika Sörenstam as the brand ambassador, emphasizing science-backed formulations for performance and healthy aging [1][2][3] Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on neuroinflammation and healthy aging, advancing a therapeutic pipeline for CNS disorders while entering the consumer longevity market with Nugevia [6][10] - The company utilizes JOTROL, a patented resveratrol-based micellar delivery platform, which enhances bioavailability and supports both clinical-stage therapies and the Nugevia supplement line [4][9][10] Product Details - Nugevia's initial formulations include GLO, MND, and PWR, designed to support skin vitality, cognitive resilience, and mitochondrial function, respectively [4][10] - The longevity market is projected to reach $8 trillion by 2030, indicating significant growth potential for Nugevia and its revenue-generating capabilities to support ongoing clinical development [4] Brand Ambassador - Annika Sörenstam, a Hall of Fame golfer with over 95 international tournament victories, will advocate for Nugevia, aligning her values of longevity and performance with the brand's mission [2][11] - Sörenstam's collaboration emphasizes the importance of scientific backing in health products, reflecting her commitment to a healthy lifestyle [3][4]

Core Insights - Jupiter Neurosciences, Inc. has officially launched Nugevia™, a consumer longevity product line, marking a significant milestone in its strategy to generate near-term revenue while advancing its clinical pipeline [1][5] - The launch of Nugevia responds to the growing global demand for scientifically validated wellness solutions aimed at extending healthspan and enhancing mental and metabolic resilience [2][4] - Nugevia's formulations utilize Jupiter's proprietary JOTROL technology, which has demonstrated a 9x improvement in bioavailability compared to traditional resveratrol products [3][9] Product Details - Nugevia's initial offerings focus on mitochondrial support, mental clarity, and "beauty from within," and will be marketed through a direct-to-consumer model starting in Q3 2025 [3][5] - The product line features "intelligent stacking" of synergistic compounds designed to enhance cellular resilience and promote system-wide optimization [4] - JOTROL is the foundation of both the Nugevia product line and ongoing therapeutic programs targeting CNS disorders such as Parkinson's and Alzheimer's disease [3][7] Strategic Implications - The launch of Nugevia is positioned as a strategic engine for growth, providing a near-term revenue stream that supports ongoing clinical trials and enhances long-term shareholder value [5][6] - The longevity market is projected to reach $8 trillion by 2030, indicating significant commercial potential for Nugevia and aligning with the company's dual-path strategy of advancing clinical therapies while monetizing its platform [5][6] - The integration of consumer products with clinical research is expected to create a self-reinforcing commercial engine, benefiting both the company's therapeutic pipeline and its business model [5][6]

PART I [Financial Statements (unaudited)](index=6&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) Unaudited Q1 2025 financial statements report a $1.53 million net loss, reduced assets, and raise substantial going concern doubts [Unaudited Condensed Consolidated Balance Sheets](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets decreased to $4.96 million, primarily due to reduced cash, with stockholders' equity falling to $3.06 million Condensed Consolidated Balance Sheet Data (unaudited) | Account | March 31, 2025 ($) | December 31, 2024 ($) | | :--- | :--- | :--- | | Cash | $2,706,469 | $3,769,510 | | Total current assets | $3,611,328 | $4,650,263 | | **Total assets** | **$4,962,826** | **$6,202,409** | | Total current liabilities | $1,889,724 | $2,009,154 | | **Total liabilities** | **$1,898,231** | **$2,030,401** | | **Total stockholders' equity** | **$3,064,595** | **$4,172,008** | [Unaudited Condensed Consolidated Statements of Operations](index=7&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) For Q1 2025, the company reported a net loss of $1.53 million, an increase from $0.63 million in Q1 2024, driven by higher operating expenses Condensed Consolidated Statements of Operations (unaudited) | Metric | Three Months Ended March 31, 2025 ($) | Three Months Ended March 31, 2024 ($) | | :--- | :--- | :--- | | Research and development | $466,745 | $98,667 | | General and administrative | $1,071,258 | $472,028 | | **Loss from operations** | **($1,538,003)** | **($570,695)** | | **Net loss** | **($1,528,867)** | **($634,100)** | | Net loss per share (Basic and diluted) | ($0.05) | ($0.02) | [Unaudited Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit)](index=8&type=section&id=Unaudited%20Condensed%20Consolidated%20Statement%20of%20Changes%20in%20Stockholders'%20Deficit) Stockholders' equity decreased from $4.17 million to $3.06 million in Q1 2025, primarily due to the net loss, partially offset by stock-based compensation - The company's total stockholders' equity decreased by approximately **$1.1 million** during the first quarter of 2025, moving from **$4,172,008** to **$3,064,595**[22](index=22&type=chunk) - The primary drivers for the change in stockholders' equity were a net loss of **$1,528,867** and non-cash stock-based compensation of **$421,454**[22](index=22&type=chunk) [Unaudited Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities significantly increased to $1.06 million in Q1 2025, leading to a cash balance decrease from $3.77 million to $2.71 million Summary of Cash Flows (unaudited) | Cash Flow Activity | Three Months Ended March 31, 2025 ($) | Three Months Ended March 31, 2024 ($) | | :--- | :--- | :--- | | Net cash flows from operating activities | ($1,063,041) | ($65,165) | | Net cash flows from financing activities | $0 | $45,000 | | **Net Change in Cash** | **($1,063,041)** | **($20,165)** | | Cash at end of period | $2,706,469 | $8,313 | [Notes to the Unaudited Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20the%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Notes detail the company's clinical-stage pharmaceutical business, express substantial doubt about going concern, and cover the December 2024 IPO, debt settlement, and strategic agreements - The company is a clinical-stage pharmaceutical company developing JOTROL, a unique resveratrol platform product, for neuro-inflammation indications like Parkinson's, Alzheimer's, Mucopolysaccharidoses Type 1, and Friedreich's Ataxia[26](index=26&type=chunk) - Management has expressed substantial doubt about the company's ability to continue as a going concern due to a history of net losses and negative operating cash flows[31](index=31&type=chunk)[32](index=32&type=chunk) - In December 2024, the company completed an IPO, selling **2,750,000 shares** at **$4.00 per share** for gross proceeds of **$11 million**[29](index=29&type=chunk)[72](index=72&type=chunk) - All convertible notes were fully repaid or converted into common stock in December 2024, eliminating the associated derivative liability, with no such liabilities existing at March 31, 2025[61](index=61&type=chunk)[62](index=62&type=chunk)[63](index=63&type=chunk) - The company has a strategic services agreement with Dominant Treasure Health Company Limited, involving a one-time payment of **$2.3 million** (accounted for as a prepaid contract) to accelerate product development and distribution in the Southeast Asian market[90](index=90&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's clinical-stage focus on JOTROL, attributing the increased Q1 2025 net loss to higher R&D and G&A expenses, and reiterates substantial going concern doubts - The company's primary focus is on its platform product JOTROL for treating neuro-inflammation, with Parkinson's Disease as the main target indication, and a Phase IIa study expected to start in Q3 2025[101](index=101&type=chunk)[104](index=104&type=chunk)[105](index=105&type=chunk) - A **$16.5 million** grant application to the NIA for a Phase II trial in MCI/early Alzheimer's Disease was not approved, and studies for this indication are paused pending biomarker results from the Parkinson's trial[107](index=107&type=chunk) - In March 2025, the company partnered with Aquanova AG to develop and launch a series of nutritional products targeting longevity and aging, with a planned market entry in Q3 2025 via a Direct-to-Consumer model[110](index=110&type=chunk) Comparison of Operating Results (Q1 2025 vs Q1 2024) | Expense Category | Q1 2025 ($) | Q1 2024 ($) | Change Driver | | :--- | :--- | :--- | :--- | | R&D Expenses | $466,745 | $98,667 | Increased activity for Parkinson's program and costs for a service agreement for the SE Asian market | | G&A Expenses | $1,071,258 | $472,028 | Full salary payments post-IPO, and higher legal, professional, and insurance fees as a public company | | Interest Expense | $1,229 | $65,756 | Decrease due to the repayment and conversion of all convertible notes in December 2024 | - The company acknowledges substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows, and anticipates needing to raise significant additional capital to fund future operations[111](index=111&type=chunk)[121](index=121&type=chunk)[122](index=122&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=34&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company states this item is not applicable, indicating no significant exposure to market risks requiring disclosure - Not applicable[139](index=139&type=chunk) [Controls and Procedures](index=34&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal control over financial reporting - Based on an evaluation as of March 31, 2025, the company's Certifying Officers concluded that disclosure controls and procedures were effective[140](index=140&type=chunk) - No material changes to the company's internal control over financial reporting occurred during the most recent fiscal quarter[142](index=142&type=chunk) PART II – OTHER INFORMATION [Legal Proceedings](index=35&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any material legal proceedings outside the ordinary course of business as of March 31, 2025 - The company may become involved in legal proceedings in the ordinary course of business, but as of the filing date, there are no material legal actions pending[83](index=83&type=chunk)[144](index=144&type=chunk) [Risk Factors](index=35&type=section&id=Item%201A.Risk%20Factors) The company refers investors to its Annual Report on Form 10-K for detailed risk factors, with no new or updated risks presented in this report - For a detailed discussion of risk factors, the company refers to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024[146](index=146&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=35&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period covered by this report - None[147](index=147&type=chunk) [Defaults Upon Senior Securities](index=35&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon its senior securities - None[147](index=147&type=chunk) [Mine Safety Disclosures](index=35&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[148](index=148&type=chunk) [Other Information](index=35&type=section&id=Item%205.%20Other%20Information) No director or officer adopted, modified, or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during Q1 2025 - No director or officer of the Company adopted, modified, or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" during the three months ended March 31, 2025[149](index=149&type=chunk) [Exhibits](index=35&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with Form 10-Q, including SOX certifications by the CEO and CFO, and Inline XBRL documents - Exhibits filed include CEO and CFO certifications under Sections 302 and 906 of the Sarbanes-Oxley Act, and various Inline XBRL files[150](index=150&type=chunk)